Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with CD33-positive acute myeloid leukemia, refractory or relapsed after standard treatment with no curative option available~* ECOG performance status 0 to 2~Exclusion Criteria:~* Therapy with gemtuzumab ozogamicin (Mylotarg) within 6 months prior to inclusion~* Allogenic transplantation within 6 months prior to inclusion~* Prior therapy (chemotherapy, targeted agents, radiotherapy) within 3 weeks except for hydroxyurea and for leukophoresis~* Previous treatment with AVE9633~* Poor kidney, liver and bone marrow functions~* Any serious active disease or co-morbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study~* Pregnant or breast-feeding women~* Patient with reproductive potential without effective birth control methods~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).